Here's why: https://t.co/q4DW5EWVHz
Congratulations to the team at @CCRG_Research (including #TPCH's K. Shekar and J. Fraser) for their work on this review
RT @KrKrramanathan: Great work @kshekar01
RT @KrKrramanathan: Great work @kshekar01
RT @Mivacrom: "responsible use in carefully selected pts advisable" Le SMUR du metro en PLS 😉
Great work @kshekar01
"responsible use in carefully selected pts advisable" Le SMUR du metro en PLS 😉
ECMO Use in COVID-19: Lessons From Past #Respiratory Virus Outbreaks—a Narrative Review | Social Reach: Low https://t.co/TgXPHV63au
RT @paomorejon: 📌#ECMO use in #COVID19: lessons from past respiratory🦠outbreaks Determine the risk-benefit ratio ⚖️ Inadequate data to de…
RT @paomorejon: 📌#ECMO use in #COVID19: lessons from past respiratory🦠outbreaks Determine the risk-benefit ratio ⚖️ Inadequate data to de…
RT @jrdelbrio: #ECMO en #COVID19 Necesitamos completar esos huecos de N/A de la tabla 4 y muchos otros para sacar conclusiones. Mañana 8…
RT @paomorejon: 📌#ECMO use in #COVID19: lessons from past respiratory🦠outbreaks Determine the risk-benefit ratio ⚖️ Inadequate data to de…
#ECMO en #COVID19 Necesitamos completar esos huecos de N/A de la tabla 4 y muchos otros para sacar conclusiones. Mañana 8 de Junio 13h (CEST) imprescindible #ELSOwebinar Why data matters! Registro en https://t.co/IyH1VcWawX https://t.co/VjwYPE0fn1
RT @paomorejon: 📌#ECMO use in #COVID19: lessons from past respiratory🦠outbreaks Determine the risk-benefit ratio ⚖️ Inadequate data to de…
RT @paomorejon: 📌#ECMO use in #COVID19: lessons from past respiratory🦠outbreaks Determine the risk-benefit ratio ⚖️ Inadequate data to de…
📌#ECMO use in #COVID19: lessons from past respiratory🦠outbreaks Determine the risk-benefit ratio ⚖️ Inadequate data to determine the efficacy, optimal👥selection & management May not be a therapy for all critical ill👥, indispensable 🏥👩🏻⚕️👨🏻⚕️🧑🏻⚕️